Lytix Biopharma announces a Proof of Concept milestone for LTX-315

27. april 2015

Lytix Biopharma AS har oppnådd viktig milepæl for LTX-315:

http://www.lytixbiopharma.com/news/294/252/Lytix-Biopharma-announces-a-Proof-of-Concept-milestone-for-LTX-315.html

Fondet Norinnova Invest AS er aksjonær i selskapet. Karl-Johan Jakola, Ansvarlig Partner i Norinnova Forvaltning AS, er styremedlem i Lytix Biopharma AS.


Alle rettigheter © Norinnova Forvaltning AS
Design: Gnist Design | WordPress